Literature DB >> 25953666

Monitoring of antibiotic consumption and development of resistance by enterobacteria in a tertiary care hospital.

R Veličković-Radovanović1,2, N Stefanović1, I Damnjanović1, B Kocić1,3, S Antić3, M Dinić1,3, J Petrović2, R Mitić2, A Catić-Djordjević1.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Antibiotics are the most frequently used drugs in hospitalized patients, but studies have shown that the prescribed antibiotics may be inappropriate and may contribute to antibiotic resistance. We carried out a survey of antibiotic consumption and antibiotic resistance in our tertiary care university hospital, from 2005 to 2013. We focus on cephalosporins, one of the most prescribed groups of antibiotics in the tertiary health care. The objective was to identify any relationship between ceftriaxone consumption and resistance by enterobacteria.
METHODS: Antibiotics consumption and antimicrobial resistance were monitored in the tertiary care university hospital from 2005 to 2013. Data on the use of antibiotics in surgical inpatients were obtained and expressed as defined daily doses per 100 bed days. Bacterial resistances were given as percentages of resistant isolates. RESULTS AND DISCUSSION: There was an increasing trend in cephalosporins consumption from 9·56 DBD (2005) to 23·32 DBD (2013), with ceftriaxone as the most frequently used cephalosporin, 3·6 DBD (2005) to 10·78 DBD (2013). E. coli and P. mirabilis resistance to ceftriaxone increased significantly from 22% in 2005 to 47% in 2013 and from 31% in 2005 to 60% in 2013, respectively. We found a significant correlation between ceftriaxone consumption and E. coli resistance (r = 0·895, P < 0·05). WHAT IS NEW AND
CONCLUSION: Our study shows that cephalosporin consumption increased from 2005 to 2013, with ceftriaxone as the most prescribed antibiotic. E. coli and P. mirabilis resistance to ceftriaxone increased significantly over the study period. E. coli resistance increased with ceftriaxone consumption.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  antibiotic consumption; bacterial resistance; ceftriaxone; cephalosporins; enterobacteria

Mesh:

Substances:

Year:  2015        PMID: 25953666     DOI: 10.1111/jcpt.12283

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  5 in total

1.  Antibiotic utility and susceptibility changes of multidrug-resistant Escherichia coli and Klebsiella spp: 5-year experience in a tertiary healthcare centre.

Authors:  Radmila Veličković-Radovanović; Nikola Stefanović; Ivana Damnjanović; Branislava Kocić; Snežana Mladenović-Antić; Marina Dinić; Jasmina Petrović; Radmila Mitić; Aleksandra Catić-Đorđević
Journal:  Eur J Hosp Pharm       Date:  2021-12-14

2.  Antibiotics: practice and opinions of Cambodian commercial farmers, animal feed retailers and veterinarians.

Authors:  Chhorvoin Om; Mary-Louise McLaws
Journal:  Antimicrob Resist Infect Control       Date:  2016-11-11       Impact factor: 4.887

3.  Is the level of knowledge a predictor of rational antibiotic use in Serbia?

Authors:  Olga J Horvat; Ana D Tomas; Milica M Paut Kusturica; Alisa V Savkov; Dragica U Bukumirić; Zdenko S Tomić; Ana J Sabo
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

4.  Differences in antimicrobial consumption, prescribing and isolation rate of multidrug resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii on surgical and medical wards.

Authors:  Vladimir Zivanovic; Ljiljana Gojkovic-Bukarica; Radisav Scepanovic; Teodora Vitorovic; Radmila Novakovic; Nenad Milanov; Zoran Bukumiric; Biljana Carevic; Jasmina Trajkovic; Jovana Rajkovic; Vladimir Djokic
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

5.  Are There Striking Differences in Outpatient Use of Antibiotics Between South Backa District, Serbia, and Some Scandinavian Countries?

Authors:  Olga Horvat; Vesna Mijatović; Boris Milijasević; Ana Tomas; Milica Paut Kusturica; Zdenko Tomić; Ana Sabo
Journal:  Front Public Health       Date:  2018-03-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.